Nanopublications LDF server

Matches in Nanopublications for { ?s ?p "[Further work is needed to identify optimal platforms for CAR-based adoptive immunotherapy for leukemia, to establish guidelines for managing toxicity, and to determine whether the remissions induced by this approach can be rendered durable.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }

• NP642207.RAVI7SzbZGTVN8fMJEpPv1Gje8pV3Q5cNeqcG_fWhWH2U130_assertion description "[Further work is needed to identify optimal platforms for CAR-based adoptive immunotherapy for leukemia, to establish guidelines for managing toxicity, and to determine whether the remissions induced by this approach can be rendered durable.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP642207.RAVI7SzbZGTVN8fMJEpPv1Gje8pV3Q5cNeqcG_fWhWH2U130_provenance.
• NP833701.RAW4mpUO_BGXkyC9WzVZyEfpfCNWzdI1Eloof0X_mve9M130_assertion description "[Further work is needed to identify optimal platforms for CAR-based adoptive immunotherapy for leukemia, to establish guidelines for managing toxicity, and to determine whether the remissions induced by this approach can be rendered durable.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP833701.RAW4mpUO_BGXkyC9WzVZyEfpfCNWzdI1Eloof0X_mve9M130_provenance.
• NP282819.RAn1xJEW2hc2fvVfd2EYXC1OtnkgxmC0WVCsIFmdNX_6o130_assertion description "[Further work is needed to identify optimal platforms for CAR-based adoptive immunotherapy for leukemia, to establish guidelines for managing toxicity, and to determine whether the remissions induced by this approach can be rendered durable.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP282819.RAn1xJEW2hc2fvVfd2EYXC1OtnkgxmC0WVCsIFmdNX_6o130_provenance.
• NP1135053.RAXqiw6AYIyM4fXYG4Cthw7nu7EKelD4ENWzXrnOy-_dk130_assertion description "[Further work is needed to identify optimal platforms for CAR-based adoptive immunotherapy for leukemia, to establish guidelines for managing toxicity, and to determine whether the remissions induced by this approach can be rendered durable.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1135053.RAXqiw6AYIyM4fXYG4Cthw7nu7EKelD4ENWzXrnOy-_dk130_provenance.
• NP1135058.RAdjv09xM7dRip_oRbqdFZEmXXTTZBjIFjVHFUQKARGVk130_assertion description "[Further work is needed to identify optimal platforms for CAR-based adoptive immunotherapy for leukemia, to establish guidelines for managing toxicity, and to determine whether the remissions induced by this approach can be rendered durable.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1135058.RAdjv09xM7dRip_oRbqdFZEmXXTTZBjIFjVHFUQKARGVk130_provenance.
• NP1135059.RAcCnfIZ8raU7IZh894_pVWx8g3My4blhjFaDnrTvxFFg130_assertion description "[Further work is needed to identify optimal platforms for CAR-based adoptive immunotherapy for leukemia, to establish guidelines for managing toxicity, and to determine whether the remissions induced by this approach can be rendered durable.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1135059.RAcCnfIZ8raU7IZh894_pVWx8g3My4blhjFaDnrTvxFFg130_provenance.
• NP710116.RAsBhHF_duNrHT9ECMWfECJZW9-ZO55baDh00u4kcRwZw130_assertion description "[Further work is needed to identify optimal platforms for CAR-based adoptive immunotherapy for leukemia, to establish guidelines for managing toxicity, and to determine whether the remissions induced by this approach can be rendered durable.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP710116.RAsBhHF_duNrHT9ECMWfECJZW9-ZO55baDh00u4kcRwZw130_provenance.
• NP1005023.RAvpMQie-rtY3gshYOWvjd9-1XvEunzL5rO0WcAPqq58I130_assertion description "[Further work is needed to identify optimal platforms for CAR-based adoptive immunotherapy for leukemia, to establish guidelines for managing toxicity, and to determine whether the remissions induced by this approach can be rendered durable.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1005023.RAvpMQie-rtY3gshYOWvjd9-1XvEunzL5rO0WcAPqq58I130_provenance.
• NP838380.RAlI_WGdP_fAEXCl-AyIz5BsROseRrTvSKTC__pZpQKJ8130_assertion description "[Further work is needed to identify optimal platforms for CAR-based adoptive immunotherapy for leukemia, to establish guidelines for managing toxicity, and to determine whether the remissions induced by this approach can be rendered durable.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP838380.RAlI_WGdP_fAEXCl-AyIz5BsROseRrTvSKTC__pZpQKJ8130_provenance.
• NP1135054.RAlC4lgfsNPyRnYecTNWKBJO0Fycai8dLLfwS774u3vFU130_assertion description "[Further work is needed to identify optimal platforms for CAR-based adoptive immunotherapy for leukemia, to establish guidelines for managing toxicity, and to determine whether the remissions induced by this approach can be rendered durable.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1135054.RAlC4lgfsNPyRnYecTNWKBJO0Fycai8dLLfwS774u3vFU130_provenance.
• NP1135055.RAtm3TvHBVGFofpLaLNCEV2z1Pl0Hacaa4CT7dAZj0Cbs130_assertion description "[Further work is needed to identify optimal platforms for CAR-based adoptive immunotherapy for leukemia, to establish guidelines for managing toxicity, and to determine whether the remissions induced by this approach can be rendered durable.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1135055.RAtm3TvHBVGFofpLaLNCEV2z1Pl0Hacaa4CT7dAZj0Cbs130_provenance.
• NP1135056.RAvcSq9wI72cfe2EiCMn26Vyy3pB2isGALPlRkuhEIzUc130_assertion description "[Further work is needed to identify optimal platforms for CAR-based adoptive immunotherapy for leukemia, to establish guidelines for managing toxicity, and to determine whether the remissions induced by this approach can be rendered durable.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1135056.RAvcSq9wI72cfe2EiCMn26Vyy3pB2isGALPlRkuhEIzUc130_provenance.
• NP1135057.RArzBP2G5HUf_DLvuu9qKLGmOnZ9YResqcvyYOCn6YyKY130_assertion description "[Further work is needed to identify optimal platforms for CAR-based adoptive immunotherapy for leukemia, to establish guidelines for managing toxicity, and to determine whether the remissions induced by this approach can be rendered durable.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1135057.RArzBP2G5HUf_DLvuu9qKLGmOnZ9YResqcvyYOCn6YyKY130_provenance.
• NP1135060.RAkZL4toKokjtEzXN64jSflqGfTVe8EX7TP-x8dR7eRXY130_assertion description "[Further work is needed to identify optimal platforms for CAR-based adoptive immunotherapy for leukemia, to establish guidelines for managing toxicity, and to determine whether the remissions induced by this approach can be rendered durable.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1135060.RAkZL4toKokjtEzXN64jSflqGfTVe8EX7TP-x8dR7eRXY130_provenance.
• NP338532.RA-ZZ9BVAn8fVZdd1w9BUMDXvNmS-CoFBLjxUrCFIQvgY130_assertion description "[Further work is needed to identify optimal platforms for CAR-based adoptive immunotherapy for leukemia, to establish guidelines for managing toxicity, and to determine whether the remissions induced by this approach can be rendered durable.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP338532.RA-ZZ9BVAn8fVZdd1w9BUMDXvNmS-CoFBLjxUrCFIQvgY130_provenance.
• NP252560.RA_l-DS5mRC4NNMvPnArJiQLraz4YX2vkqgfBNzB94xQw130_assertion description "[Further work is needed to identify optimal platforms for CAR-based adoptive immunotherapy for leukemia, to establish guidelines for managing toxicity, and to determine whether the remissions induced by this approach can be rendered durable.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP252560.RA_l-DS5mRC4NNMvPnArJiQLraz4YX2vkqgfBNzB94xQw130_provenance.